Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on February 9, 2021. The report details a transition services agreement with Kevin Peters, M.D., following his planned termination as Chief Scientific Officer and Chief Medical Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Executive Departure: Dr. Kevin Peters is departing his roles as Chief Scientific Officer and Chief Medical Officer.
- Transition Period: Dr. Peters will provide transitional services until the earlier of March 31, 2021, or the conclusion of the ongoing RESCUE trial with MTEC.
- Compensation Structure:
- Standard Termination: 12 months of base salary, 12 months of medical/dental benefits (or COBRA), and acceleration of time-based stock options vesting for an additional 12 months.
- Change in Control: If a change in control occurs within three months of termination, Dr. Peters receives a lump sum equal to 1.5 times (base salary + target bonus), 18 months of medical/dental benefits, and full acceleration of time-based stock options.
Guidance, Outlook, and Risks
The filing contains no financial guidance or outlook. The primary risk disclosed relates to the loss of key scientific and medical leadership, mitigated by a transition period tied to the ongoing RESCUE clinical trial. The agreement includes a general release of claims and a nondisparagement provision.
Investor Verification Checklist
- Verify the exact end date of the RESCUE trial to determine the duration of Dr. Peters' transition services.
- Confirm the specific value of Dr. Peters' base salary and target annual incentive bonus to calculate potential severance liabilities.
- Review the full text of the Transition Services Agreement (Exhibit 10.1) for specific conditions regarding the "Change in Control" definition.
- Assess the impact of losing the Chief Scientific Officer and Chief Medical Officer on the company's clinical development timeline.